Opinion|Videos|October 18, 2024

Long-term NMOSD Data

Sean Pittock, MD, discusses the long-term efficacy and safety results of other FDA-approved treatments for neuromyelitis optica spectrum disorder, including satralizumab, inebilizumab, and the off-label use of rituximab.

Video content above is prompted by the following:

Can you also comment on long-term efficacy and safety results with other FDA-approved treatments, including satralizumab, inebilizumab, and off-label use of rituximab?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME